Brief: Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-In-Class Profile Of The Regimen Of Bemnifosbuvir And Ruzasvir For The Treatment Of Hepatitis C Virus At Easl Congress 2026
27/05/2026 14:30
BRIEF-Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-In-Class Profile Of The Regimen Of Bemnifosbuvir And Ruzasvir For The Treatment Of Hepatitis C Virus At Easl Congress 2026 May 27 (Reuters) - Atea Pharmaceuticals Inc AVIR.O:
ATEA PHARMACEUTICALS PRESENTS NEW DRUG-DRUG INTERACTION RESULTS SUPPORTING POTENTIAL BEST-IN-CLASS PROFILE OF THE REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR THE TREATMENT OF HEPATITIS C VIRUS AT EASL CONGRESS 2026
ATEA PHARMACEUTICALS INC - PHASE 1 STUDY SHOWS BEM/RZR SAFE AND WELL-TOLERATED WITH OR WITHOUT OMEPRAZOLE
ATEA PHARMACEUTICALS INC - OMEPRAZOLE AT 20 MG DOES NOT AFFECT BEM/RZR PLASMA EXPOSURE; 40 MG SLIGHTLY REDUCES EXPOSURE
Source text: ID:nGNX7dJ8NX
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM